UB Paderborn / Katalog / Suche / in CDI

1 – 13 von 13

Sortiert nach

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

The lancet oncology, 2019-01, Vol.20 (1), p.43-56

2019

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Leukemia, 2020-09, Vol.34 (9), p.2354-2363

2020

Link zum Volltext

Verfügbarkeit prüfen

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Haematologica (Roma), 2022-09, Vol.107 (9), p.2108-2120

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia

Annals of hematology, 2018-11, Vol.97 (11), p.2153-2161

2018

Link zum Volltext

Verfügbarkeit prüfen

Five‐year survival follow‐up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine‐refractory chronic lymphocytic leukaemia: a short report

British journal of haematology, 2020-05, Vol.189 (4), p.689-693

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of MRD Eradication on Survival Outcomes in CLL Patients with Different IGHV Mutation Status

Clinical lymphoma, myeloma and leukemia, 2019-09, Vol.19, p.S273-S273

2019

Link zum Volltext

Verfügbarkeit prüfen

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

BLOOD, 2018-11, Vol.132 (Supplement 1), p.5569-5569

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Ibrutinib in the Treatment of First Early Relapses of CLL

Clinical lymphoma, myeloma and leukemia, 2018-09, Vol.18, p.S216-S216

2018

Link zum Volltext

Verfügbarkeit prüfen

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Blood, 2018-11, Vol.132 (Supplement 1), p.691-691

2018

Link zum Volltext

Verfügbarkeit prüfen

9 Year Follow-up After Initial Treatment with FC and FCR Regimens In Chronoc Lymphocytic Leukemia - Impact of pretreatment CIRS

Blood, 2011-11, Vol.118 (21), p.4616-4616

2011

Link zum Volltext

Verfügbarkeit prüfen

Prospective Evaluation of Safety and Efficacy of BR Regimen in Previously Untreated CLL Patients

Clinical lymphoma, myeloma and leukemia, 2016-09, Vol.16, p.S46-S47

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy Of Different Therapeutic Approaches In Blastic Phase Of Chronic Myeloid Leukemia: Single Centre Experience

Blood, 2013-11, Vol.122 (21), p.5173-5173

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 13 von 13

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(13)

Sprache

Englisch
(13)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Blood
(5)
Clinical Lymphoma, Myeloma And Leukemia
(3)
Annals Of Hematology
(1)
British Journal Of Haematology
(1)
Haematologica
(1)
Leukemia
(1)
The Lancet Oncology
(1)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial

Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia

Five‐year survival follow‐up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine‐refractory chronic lymphocytic leukaemia: a short report

Impact of MRD Eradication on Survival Outcomes in CLL Patients with Different IGHV Mutation Status

Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia

Efficacy of Ibrutinib in the Treatment of First Early Relapses of CLL

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

9 Year Follow-up After Initial Treatment with FC and FCR Regimens In Chronoc Lymphocytic Leukemia - Impact of pretreatment CIRS

Prospective Evaluation of Safety and Efficacy of BR Regimen in Previously Untreated CLL Patients

Efficacy Of Different Therapeutic Approaches In Blastic Phase Of Chronic Myeloid Leukemia: Single Centre Experience

First Line BR in Chronic Lymphocytic Leukemia Patients: Interim Results of Russian Norma Trial

Suchergebnisse filtern